Plain-English translation of NCT06475781 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 clinical trial testing , a new medication designed to help people with a serious condition called pulmonary hypertension associated with interstitial lung disease (PH-ILD). In this study, some participants will receive the medication at one of two dose levels, while others will receive a placebo (a pill with no active medication) to compare how well the treatment works. The trial will follow about 126 people over 12 weeks to see if this medication is safe and effective.
Interstitial lung disease is a serious condition that can lead to high blood pressure in the lungs, making it hard to breathe and affecting the heart. Currently, there are limited treatment options for this combination of problems, so researchers are testing whether this new medication might help improve symptoms and lung function.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic for screening to confirm you have the condition, then return on Day 1 to start taking either the medication or placebo once daily. Over the next 12 weeks, you'll have in-person visits at weeks 2, 4, 8, and 12, plus phone check-ins at weeks 3, 6, and 10. At the beginning and end of the study, you'll undergo a heart catheterization procedure (a test that measures pressures in your heart and lungs) and chest imaging. You'll also have a follow-up safety visit after week 12 to ensure you're doing well.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
Taiwan